

Ref: EPL/CS/SE/0042/2025

Date: June 17, 2025

To,

<b>National Stock Exchange of India Limited</b> <b>Exchange Plaza, C-1, Block G,</b> <b>Bandra Kurla Complex, Bandra (East),</b> <b>Mumbai - 400 051</b>	<b>BSE Limited</b> <b>P J Towers,</b> <b>Dalal Street,</b> <b>Mumbai- 400 001</b>
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

Dear Sir/Madam,

**Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation of a Wholly-owned Subsidiary**

We refer to our disclosure dated May 22, 2025 (copy attached), pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), related to proposed incorporation of a wholly-owned subsidiary (WoS) by the name "Emcure Generics Private Limited" in Pune, Maharashtra, India with objects to manufacture, promote, sale and distribute pharmaceuticals and other related product(s). In relation to same, we would like to inform that instead of using the name "Emcure Generics Private Limited, the Company had applied for availability of name "Emcure Lifesciences Private Limited" to the Registrar of Companies (ROC), Pune, with the same objects and received approval for the same.

Further, the ROC has approved the application of incorporation of "**Emcure Lifesciences Private Limited**", a WoS, on June 17, 2025. All the particulars except name, as mentioned in the disclosure dated May 22, 2025, remains the same.

You are requested to take the above information on your records.

Thanking you,

**For Emcure Pharmaceuticals Limited**

**Chetan Sharma**  
**Company Secretary & Compliance Officer**  
**Membership Number: F8352**

### **Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Ref: EPL/CS/SE/0032/2025

Date: May 22, 2025

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai- 400 001
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

Dear Sir/Madam,

**Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of proposed incorporation of a Wholly-owned Subsidiary**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), read with Schedule III of aforesaid regulation and SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November, 2024, we would like to inform that the Board of Directors of the Company in their meeting held today i.e. May 22, 2025, has *inter-alia* approved the incorporation of a wholly-owned Subsidiary by the name "**Emcure Generics Private Limited**" in Pune, Maharashtra, India.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the Listing Regulations are provided in **Annexure A**, enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

CHETAN  
RAJENDRA  
SHARMA  
Digitally signed by  
CHETAN RAJENDRA  
SHARMA  
Date: 2025.05.22  
15:43:28 +05'30'

**Chetan Sharma**

**Company Secretary & Compliance Officer**

**Membership Number: F8352**

## **Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

**Annexure A**

**Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:**

<b>Sr. No</b>	<b>Particulars</b>	<b>Information</b>
a)	Name of the target entity, details in brief such as size, turnover etc.	<b>Name:</b> Emcure Generics Private Limited  <b>Proposed Authorized Share Capital:</b> Rs. 10,00,00,000/- (Rupees Ten Crores only)  <b>Proposed Paid-up Share Capital:</b> Rs. 1,00,000/- (Rupees One Lakh only)  <b>Turnover:</b> Not Applicable, as the entity is yet to be incorporated.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The proposed entity would be a wholly-owned Subsidiary (WoS) of the Company and hence once incorporated, the WoS will be a related party of the Company and other subsidiaries.  Save and except what is mentioned above, the Promoters / Promoter Group / Group Companies are not interested in the transaction.
c)	Industry to which the entity being acquired belongs	Pharmaceuticals
d)	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	WoS is being incorporated to manufacture, promote, sale and distribute pharmaceuticals and other related product(s).
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f)	Indicative time period for completion of the acquisition	Not Applicable
g)	Nature of consideration - whether cash consideration or share swap and details of the same	100% subscription to initial paid-up share capital of Rs. 1,00,000/- (Rupees One Lakh only) is in cash.
h)	Cost of acquisition or the price at which the shares are acquired	At face value of Rs.10/- per share.

**Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

## Emcure

i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	100% subscription to the share capital of the proposed WoS.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the proposed WoS is yet to be incorporated.

### Emcure Pharmaceuticals Limited

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251